Can IBD Patients Safely Use Semaglutide? Real-World Data Offers a Clear Answer

Key Takeaways

• In a real-world cohort of 47,424 adults with both IBD and obesity identified in the TriNetX network, semaglutide produced weight loss outcomes comparable to those seen in non-IBD populations, with no increased risk of IBD-related adverse events. 
• Semaglutide outperformed liraglutide, phentermine-topiramate, bupropion-naltrexone, and orlistat, though tirzepatide produced greater weight loss than semaglutide in this analysis. 
• For medical affairs, market access, and HEOR teams working on GLP-1 strategy, this study provides the real-world safety and efficacy foundation needed to support label expansion discussions, formulary access decisions, and patient selection frameworks in a population that has historically lacked large-scale evidence. 

GLP-1 receptor agonists are reshaping the obesity treatment landscape, and semaglutide is leading that shift. For most patient populations, the evidence base is established and the commercial momentum is clear. For patients with inflammatory bowel disease (IBD), the picture is more complicated.

IBD patients are increasingly affected by obesity, driven by the same demographic and lifestyle factors as the broader population and compounded by the effects of long-term corticosteroid use. Semaglutide is the most effective weight-loss tool widely available. Yet prescribers have been cautious about deploying it in this population, and that caution has been reasonable: IBD involves a chronically inflamed gastrointestinal (GI) tract, and the GI side effect profile of GLP-1 receptor agonists raised legitimate questions about tolerability and disease exacerbation in these patients. 

Without large-scale real-world data (RWD), that caution has been difficult to counter with evidence. An independent study conducted by Desai et al. (Inflamm Bowel Dis. 2025 Mar 3;31(3):696-705) utilizing the TriNetX LIVE™ platform changes that. 

The Evidence Gap This Study Fills

Prior to this analysis, the data on GLP-1 receptor agonist use in IBD patients was limited to small studies and case series. That evidence gap had real commercial consequences: uncertainty about safety in this population slowed formulary inclusion discussions, complicated patient selection frameworks, and left medical affairs teams without the real-world foundation needed to support access conversations with payers and health systems. 

The study addresses that gap directly, drawing on a population large enough to detect safety signals and robust enough to support comparative efficacy analysis across multiple anti-obesity agents. 

What the Study Found

Researchers identified 47,424 adults with both IBD and obesity across the TriNetX LIVE™ network, one of the largest real-world cohorts of this patient population assembled for this type of analysis. Of those, 150 received semaglutide and formed the matched treatment cohort for the primary analysis. The cohort size reflects the real-world adoption curve of semaglutide at the time the data were drawn, and the high variability in weight-change estimates it introduces is acknowledged in the study’s limitations. The findings on IBD-related safety held across the analysis despite that constraint. 

The study compared weight loss outcomes and IBD-related adverse events across semaglutide and four conventional anti-obesity medications: liraglutide, phentermine-topiramate, bupropion-naltrexone, and orlistat. 

The findings resolve the central clinical and commercial question directly. 

• Semaglutide produced weight loss in IBD patients comparable to non-IBD populations. The concern that IBD-related GI burden or malabsorption might attenuate semaglutide’s efficacy in this population was not borne out. Patients with IBD achieved weight loss outcomes consistent with what has been observed in broader semaglutide trials and real-world studies. 
• No increased risk of IBD-related adverse events was observed. This is the finding that directly addresses prescriber hesitancy. GI side effects associated with GLP-1 receptor agonists, including nausea, vomiting, and altered motility, did not translate into elevated rates of IBD flares, hospitalizations, or other disease-specific adverse outcomes in this cohort. The safety profile in IBD patients was consistent with the established profile in non-IBD populations. 

For teams building the evidence case for GLP-1 use in complex patient populations, this is the data that moves the conversation forward. 

Why This Matters for GLP-1 Commercial and Market Access Strategy

The commercial significance of this study extends beyond IBD as a therapeutic area. GLP-1 receptor agonists are under active evaluation for use across a widening range of patient populations, and payers, health systems, and formulary committees are increasingly asking for population-specific real-world safety and efficacy data before expanding access. 

IBD represents exactly the kind of complex comorbidity population where that evidence has been absent. Approximately 15 to 40 percent of IBD patients are affected by obesity, depending on disease type and patient characteristics. This is not a small or peripheral group. It is a clinically significant population that has been effectively excluded from the full benefit of the most effective anti-obesity pharmacotherapy available because the evidence to support its use confidently was not there. 

This study provides that evidence. For medical affairs teams, it supports the clinical narrative that semaglutide is appropriate for IBD patients who meet obesity treatment criteria, without requiring additional safety caveats beyond standard GLP-1 monitoring. For market access and formulary teams, it provides the real-world comparative data that supports inclusion of IBD patients in coverage criteria without carve-outs or additional prior authorization requirements. For Health Economics and Outcomes Research (HEOR) teams, it establishes a foundation for modeling long-term weight-related outcomes and comorbidity burden reduction in this population. 

The anti-inflammatory properties of GLP-1 receptor agonists, increasingly documented in the literature, add a layer of biological plausibility to these findings. Whether those properties contribute to the absence of IBD-related adverse events in this cohort is a question this study raises without resolving, and one that points toward productive future research. 

Closing the Evidence Gap, Opening the Access Conversation

IBD patients carry a disproportionate obesity burden and have been underserved by the GLP-1 evidence base. This study closes that gap at scale, with a cohort large enough to detect risk and a comparator framework broad enough to establish relative efficacy across the available anti-obesity treatment options. 

The result is a real-world safety and efficacy foundation that did not previously exist for this population, and one that commercial, market access, and HEOR teams can use directly in label expansion discussions, formulary negotiations, and patient selection framework development. 

About Jeffrey Brown, PhD 

With more than 25 years of experience in research and consulting, Jeff is an internationally recognized expert in the use of RWD to support the evidentiary needs of regulatory agencies and medical product sponsors and an expert in the assessment of data quality of RWD resources.